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MicroRNAs are small non-coding RNAs that range in length from 18 to 24 nucleotides.
As one of the most extensively studied microRNAs, microRNA-21 (miR-21) is highly
expressed in many mammalian cell types. It regulates multiple biological functions such
as proliferation, differentiation, migration, and apoptosis. In this review, we summarized
the mechanism of miR-21 in the pathogenesis of various liver diseases. While it is
clear that miR-21 plays an important role in different types of liver diseases, its use
as a diagnostic marker for specific liver disease or its therapeutic implication are not
ready for prime time due to significant variability and heterogeneity in the expression of
miR-21 in different types of liver diseases depending on the studies. Additional studies
to further define miR-21 functions and its mechanism in association with each type of
chronic liver diseases are needed before we can translate the bedside observations into
clinical settings.
Keywords: miRNA-21, viral hepatitis, non-alcoholic fatty liver disease, alcohol liver disease (ALD), hepatocellular
carcinoma
INTRODUCTION
MicroRNAs (miRNAs) are small non-coding RNAs with 18–24 nucleotides in length. MiRNAs can
bind to target mRNAs and negatively regulate gene expression (1). MiRNAs are transcribed by
RNA polymerase II as part of capped and polyadenylated primary transcripts (pri-miRNAs) that
can be either protein-coding or non-coding (2). The biogenesis of miRNAs can be regulated either
at the transcriptional level by specific transcription factors or at the post-transcriptional level by
changes in processing (3, 4). MiRNAs target and regulate essentially all biological processes and cell
types, and influence complex programs of gene expression in several cellular processes. Particular
miRNAs emerge as principal regulators that control major cell functions in various physiological
and pathophysiological settings.
MicroRNA-21 (miR-21) gene is located on chromosome 17 of Homo sapiens and highly
conserved (Figure 1A). Its promoter described by Fujita et al. has several conserved enhancer
elements including binding sites for activation protein 1 (AP-1; composed of Fos and
Jun family proteins), E26 transformation-specific family transcription factor PU1 (Ets/PU1),
CCAAT/enhancer binding proteins α (C/EBPα), nuclear factor I (NFI), serum response factor
(SRF), p53 and signal transducer and activator of transcription 3 (STAT3) (5, 6). At the cellular
level, miR-21 is located in the cytosol (7), extracellular exosome (8), and at the organ level, miR-21
is found in peripheral blood, bone marrow, liver, lung, kidney, Intestine, colon, and thyroid (9).
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FIGURE 1 | (A) miR-21 is highly conserved across the species, (B) the functions of miR-21 on intracellular biological processes.
Functionally, miR-21 regulates its targets via interaction with
the 3′ untranslated region (UTR) binding involving in post-
transcriptional gene silencing (10). It is predicted using
Abbreviations: ALD, alcohol-associated liver disease; AP-1, activation protein
1; C/EBPα, CCAAT/enhancer binding proteins α; Ets/PU1, E26 transformation-
specific family transcription factor PU1; FABP7, fatty acid binding protein 7;
FASLG, Fas ligand; Foxo1, forkhead box O1; HBP1, HMG-Box transcription
factor 1; HCC, hepatocellular carcinoma; HMGCR, 3-hydroxy-3-methylglutaryl-
coA reductase; HNF4-α, hepatocyte nuclear factor 4 alpha; IL-12, interleukin 12;
Insig2, insulin induced gene 2; IRAK1, interleukin 1 Receptor Associated Kinase 1;
KC, Kupffer cells; KLF5, Kruppel Like Factor 5; MMP, matrix metallopeptidase;
MyD88, myeloid differentiation primary response 88; NAFLD, non-alcoholic
fatty liver disease; NASH, non-alcoholic steatohepatitis; NFI, nuclear factor I;
NOX4, NADPH oxidase 4; PDCD4, programmed cell death 4; PPARα, peroxisome
proliferator-activated receptor alpha; PTEN, phosphatase and tensin homolog;
RECK, reversion inducing cysteine rich protein with kazal motifs; SMAD, a family
of proteins similar to the gene products of the Drosophila gene ’mothers against
decapentaplegic’ (Mad) and theC. elegans gene Sma.; Spry1, sprouty RTK signaling
antagonist 1; SREBP1, sterol regulatory element binding protein; SRF, serum
response factor; STAT3, signal transducer and activator of transcription 3; TFDP3,
transcription factor Dp family member 3 TGF-β, transforming growth factor-
β; TIMP-3, tissue inhibitors of metalloproteinases 3; VEGF, vascular endothelial
growth factor.
computational algorithms that 175 genes involving in biological
regulation, cellular and metabolic processes are under regulation
of miR-21 [Figure 1B; (11)], however, relatively few have been
experimentally validated (Table 1).
MiR-21 is upregulated in many biological processes, including
inflammation, fibrosis, and cancer (5). Increasing evidence
has demonstrated the important role of miR-21 in several
types of liver diseases. In this current review, we summarized
the mechanism of miR-21 in common liver diseases, such
as viral hepatitis, non-alcoholic fatty liver disease (NAFLD),
alcohol-associated liver disease (ALD), and hepatocellular
carcinoma (HCC).
MIR-21 IN VIRAL HEPATITIS
Host miRNAs may target viral genomes or cellular factors,
positively or negatively regulating viral infection (30). Viral
infections can affect cellular miRNA expression levels and create
a favorable environment for their survival and pathogenic
effects (30). Serum levels of miR-21 were increased in patients
infected with Hepatitis B virus (HBV) (31, 32). Although there
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TABLE 1 | Reported gene targets known to be regulated by miR-21.
Targets Gene name Mainly function Disease References
FASLG Fas ligand Regulation of the immune system and the progression of cancer ALD, HCC (12, 13)
PTEN Phosphatase and tensin homolog Regulation of the cell cycle lung squamous
carcinoma, HCC
(14, 15)
TFDP3 Transcription Factor Dp Family Member 3 Regulation of the cell cycle Lung cancer (16)
HBP1 HMG-Box Transcription Factor 1 Transcriptional repressor, regulation of the cell cycle NAFLD and HCC (17)
HMGCR 3-Hydroxy-3-Methylglutaryl-CoA Reductase A key enzyme of mevalonate pathway, which produce cholesterol
and isoprenoids.
NAFLD (18)
FABP7 Fatty Acid Binding Protein 7 Fatty acid uptake, transport, and metabolism NAFLD (19)
HIF-1a Hypoxia-inducible factor 1-alpha A transcriptional regulator of cell response to hypoxia, involving cell
survival, tumor invasion, and angiogenesis
ovarian cancer (20)
PDCD4 Programmed Cell Death 4 Plays a role in apoptosis breast cancer (21, 22)
PPARα Peroxisome proliferator-activated receptor
alpha
Regulation of lipid metabolism in liver NAFLD (23)
TGF-β Transforming growth factor, beta Multifunctional cytokine, regulation of immune cells, cell growth. spinal cord injury, colon
cancer
(24, 25)
SMAD7 SMAD Family Member 7 Inhibitor of the TGF-β signaling NASH (26)
IL-12 Interleukin 12 A T cell-stimulating factor, activation of immune response HCC (27)
RECK Reversion-inducing cysteine-rich protein with
Kazal motifs precursor
Metalloendopeptidase inhibitor, wnt-protein binding HCC (28)
TIMP-3 Tissue inhibitors of metalloproteinases 3 Inhibitor of the matrix metalloproteinases Liver fibrosis, HCC (28, 29)
was no direct evidence to prove that miR-21 was responsible
for HBV infection or replication, some studies showed that
miR-21 was essential in the HBV x protein (HBx) induced
non-tumor to tumor transformation (27, 31, 33), mechanically
through phosphatase and tensin homolog/phosphoinositide
3-kinase/protein kinase B (PTEN/PI3k/Akt) signaling
pathway (34).
Hepatitis C virus (HCV) increases the expression of miR-21
in hepatocyte cell lines and primary human hepatocytes (35).
Clinical data showed that miR-21 expression in liver tissues
was associated with viral load and the level of fibrosis in liver
biopsies of patients with HCV infection (36). Chen et al., showed
that during HCV infection miR-21 negatively regulated IFN-α
signaling by inhibiting myeloid differentiation primary response
88 (MyD88) and Interleukin 1 Receptor Associated Kinase 1
(IRAK1) (37).
MIR-21 IN NON-ALCOHOLIC FATTY LIVER
DISEASE (NAFLD)
NAFLD is one of the most common chronic liver diseases which
is associated with metabolic syndrome. It represents a broad
spectrum of histopathological changes ranging from simple
steatosis, steatohepatitis (NASH), and cirrhosis (38, 39). Hepatic
miR-21 expression is increased in animal models and patients
with NAFLD/NASH (23, 40, 41); however, serum miR-21 levels
in NAFLD patients when compared to controls were varied
depending on the studies. One study showed that serum miR-21
level was lower in 25 NAFLD patients than those in 12 healthy
controls (18), the other study claimed that serum level of miR-
21 was higher in patients with NAFLD (42). Several studies
showed that miR-21 relies on a complex transcription network
to regulate glucose and lipid metabolism in hepatocytes. MiR-21,
in part, promotes hepatic lipid accumulation by interacting with
several factors, such as sterol regulatory element binding protein
(SREBP1) (17, 43), 3-hydroxy-3-methylglutaryl-co-enzyme A
reductase (HMGCR) (18), fatty acid binding protein 7 (FABP7)
(19). In addition, Calo et al. (44) revealed a new role for miR-21 in
hepatocytes in promoting hepatic insulin resistance and steatosis
in diet-induced obese mice through regulation of forkhead box
protein O1 (Foxo1), insulin induced gene 2 (Insig2), STAT3 and
Hepatocyte nuclear factor 4 alpha (HNF4-α). Lack of hepatic
miR-21 was sufficient to improve glucose tolerance, insulin
sensitivity as well as to prevent hepatic steatosis and fatty acid
uptake. MiR-21 also contributes to cell injury, inflammation
and fibrosis, through its inhibition of peroxisome proliferator-
activated receptor alpha (PPARα) signal pathway (23). Taken
together, miR-21 may therefore be implicated at different steps of
the NAFLD progression in a cell-specific manner: (1) early steps
of lipid accumulation and steatosis onset in hepatocytes and/or
(2) inflammation and fibrosis at later stages of the disease (45).
MIR-21 IN ALCOHOL ASSOCIATED LIVER
DISEASE (ALD)
ALD comprises of histopathological changes similar to those of
NAFLD in patients with excessive alcohol use. Several miRNAs
are aberrantly expressed after alcohol-induced liver injury. In
animal models of mice fed with ethanol via intragastric ethanol
feeding (12) or 5 weeks Lieber Decarli ethanol feeding (12),
the levels of hepatic miR-21 were found to be differentially
overexpressed in mice fed with ethanol compared to pair-fed
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controls. The induction of hepatic miR-21 is believed to exert
its protective effect against liver injury secondary to alcohol.
First, overexpression of miR-21 increases cell survival during
alcohol-induced liver injury (12). Second, alcoholic hepatitis
and alcoholic cirrhosis lead to alterations of tissue repair; a
process involving a series of death receptor signaling pathways
(46, 47). MiR-21 is a putative mediator of hepatic damage and
crucial in tissue repair during alcohol exposure (12). Third,
miR-21 may serve as a key regulator of liver regeneration in
response to liver injury secondary to alcohol consumption (48).
In addition to the findings in animal model, there are 2 lines
of evidence supporting the important role of miR-21 in ALD.
Integrative miRNA profiling of human liver tissues revealed an
important dysregulation of miRNA expression among patients
with AH compared to controls (49). Among miRNAs which
were differentially expressed frommiRNA profiling, hepatic miR-
21 was confirmed and validated to be significantly upregulated
in patients with AH (49). Despite the evidence suggesting the
protective role of miR-21 in ALD, an in-depth analysis to further
study the molecular mechanism on the role of miR-21 on the
3 key histological pathologies commonly observed in alcoholic
hepatitis; steatosis, inflammation, and fibrosis, are lacking. The
processes involving in the spectrum of alcohol-induced liver
injury are complex and involved the cross talk between the
hepatocytes, kupffer cells (KCs), and stellate cells. Apoptotic
hepatocytes secondary to alcohol-induced liver injury promote
secretion of inflammatory and pro-fibrogenic cytokines from
KCs (47). The role of KCs in the pathogenesis of liver fibrosis
has been shown indispensable since macrophage depletion
blunts the development of fibrosis (50). As miR-21 is present
in the hepatocyte (12) and inflammatory cells/macrophage
(51), and stellate cells (52), the specific role of miR-21 from
different cell types contributing to ALD pathogenesis should be
further studied.
MIR-21 IN LIVER FIBROSIS AND
HEPATOCELLULAR CARCINOMA (HCC)
MiR-21 has been shown to promote fibrogenesis in muscles
and various organs including heart, kidneys, lungs, and liver
(53). Clinical data also showed that miR-21 expression was up-
regulated in liver of patients with biliary atresia-induced liver
fibrosis (54). In liver, miR-21 induces fibrosis by activating
hepatic stellate cells (HSCs) and collagen synthesis (52, 55, 56).
Mechanically, the over expression of miR-21 promotes oxidation,
increases in collagen production and activates angiotensin
via sprouty RTK Signaling Antagonist 1 (Spry1)/ERK/NF-
κB, PTEN/Akt, programmed cell death 4 (PDCD4)/AP-1,
Smad7/Smad2/3/NADPH oxidase 4 (NOX4) pathways (52, 57,
58). Recently, research showed that in an methionine choline
deficient diet model of NASH-associated liver damage, miR-
21 knockout results in decrease of steatosis, inflammation, and
lipoapoptosis, with impairment of fibrosis (59). Similarly, in
a different study, the loss of miR-21 expression resulted in
decreased collagen deposition and expression of fibrotic markers
transforming growth factor-β1 and α-smooth muscle actin in
bile duct ligation mice model (60). Despite the evidence on the
role of miR-21 and fibrosis, a recent study found that antisense
inhibition or genetic deletion of miR-21 does not alter HSC
activation or liver fibrosis in CCL4 induced liver fibrosis mice
models (29).
MiR-21 is an “onco-miR,” and miR-21 is frequently up-
regulated in human solid malignancies, such as tumors of
breast, colon, lung, pancreas, prostate, liver, and stomach
(61). MiR-21 is an established survival factor during liver
injury and hepatocellular carcinoma development. Clinical data
showed that miR-21 was significantly upregulated in both
HCC tissues and serum (62–64). Although miR-21 expression
in HCC tissues did not predict overall survival (64), studies
showed that increased expression of miR-21 was significantly
correlated with tumor progression and could be a novel potential
biomarker for HCC prognosis (63–65). Mechanically, miR-21
promotes migration and invasion in HCC through the miR-
21-PDCD4-AP-1 feedback loop (66). Upregulation of miR-
21 can activate phosphatase and tensin homolog (PTEN),
which activates phosphatidylinositol 3-kinase signaling to AKT
and contributes to progression of HCC (67). Moreover, miR-
21 promotes cell migration and invasion of hepatocellular
carcinoma by targeting Kruppel Like Factor 5 (KLF5) (68). In
addition, HCC cells secreted exosomal miRNA-21 that directly
targeted PTEN, leading to activation of pyruvate dehydrogenase
kinase 1 (PDK1)/AKT signaling in HSCs; then promoted cancer
progression by secreting angiogenic cytokines, including vascular
endothelial growth factor (VEGF), matrix metallopeptidase 2
(MMP2), MMP9, basic fibroblast growth factor (bFGF), and
transforming growth factor-β (TGF-β) (69). In two separate HCC
tumor xenograft models, treatment with specific single-stranded
oligonucleotide inhibitors of miR-21 (anti-miRNAs) suppresses
HCC growth (70).
TABLE 2 | Summary of miRNA-21 dysregulation in various liver diseases.
MiR-21
dysregulation
Sample type Detect
methods
Liver
diseases
References
Up-regulation Human serum RT-qPCR HBV (31, 32)
Up-regulation,
correlated with
fibrotic stage, viral
load
Human liver RT-qPCR HCV (36)
Up-regulation Cell RT-qPCR HCV (36)
Up-regulation Mice liver RT-qPCR High fat diet
model
(23)
Up-regulation Human liver microarray NASH (23)
Down-regulation Human serum RT-qPCR NAFLD (18)
Up-regulation Human serum RT-qPCR NAFLD (42)
Up-regulation Mice liver microarray ALD (12)
Up-regulation Human liver microarray AH (49)
Up-regulation Human liver RT-qPCR Liver fibrosis
with biliary
atresia
(54)
Up-regulation Human liver,
serum
RT-qPCR HCC (62, 63)
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POTENTIAL ROLES OF MIR-21 AS
DIAGNOSTIC AND THERAPEUTIC
TARGETS FOR LIVER DISEASES
While it is clear that miR-21 plays an important role in
different types of liver diseases, its use as a diagnostic marker
for specific liver disease or its therapeutic implication are
not ready for prime time. Circulating miR-21 as a diagnostic
marker for disease staging such as in patients with NAFLD
yielded contradicting results (18, 42). More importantly, the
lack of standard operating procedures and the uniform method
to normalize the level of miR-21 with gatekeeping genes are
also problematic to adopt to use of miR-21 as the diagnostic
tool. Targeting miRNA has previously been conducted for the
treatment of hepatitis C infection (36), however, more studies are
needed to further explore specific mechanisms of miR-21 in the
pathogenesis of various types of liver diseases before its use as a
therapeutic intervention.
SUMMARY
Dysregulation of MiR-21 is common in several types of chronic
liver diseases (Table 2). However, in each type of liver disease,
there is a variability and heterogeneity in the expression of
miR-21 depending on the studies. The underlying explanation
may be due to the use of different animal models and lack
of standardized procedures and methods to normalize its level.
There are several pitfalls in using miR-21 as the therapeutic target
or as potential biomarkers for specific types of liver diseases.
Additional studies to further define miR-21 functions and its
mechanism in association with each type of chronic liver diseases
are needed before we can translate the bedside observations into
clinical settings.
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